Leandro Oliveira

Leandro Oliveira

Auto-generated profile, based on publicly available information

Leandro Oliveira

Universidade Estadual Paulista “Júlio de Mesquita Filho”, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Arquivos do Instituto Biológico
Verified
Journal Article
Open access
LOLeandro Oliveira
Leandro Oliveira
RMRicardo Fagundes Marques
Ricardo Fagundes Marques
AJAntonio Carlos da Silva Junior
Antonio Carlos da Silva Junior
SMSidnei Roberto de Marchi
Sidnei Roberto de Marchi
DMDanilo Martins
Danilo Martins

1 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
CDCaroline Dohanik
Caroline Dohanik
LOLeandro Gonzaga de Oliveira
Leandro Gonzaga de Oliveira
RORoberta Ondei
Roberta Ondei
DCDennis Christensen
Dennis Christensen
DFDiego dos Santos Ferreira
Diego dos Santos Ferreira
GGGisele Assis Castro Goulart
Gisele Assis Castro Goulart
Adjuvants are usually a fundamental part of a vaccine formulation due to their ability to increase immunogenicity, but their safety and efficacy must be established in preclinical studies. In this sense, we evaluated Emulsivant 70, a new ready‐to‐use adjuvant based on water‐in‐oil (W/O) emulsion for veterinary vaccines. Its performance was compared with the commercial adjuvant Montanide ISA 70 in mice immunized with tetanus toxoid (TT) and inactivated influenza PR8. No substantial changes in renal or hepatic biochemical markers (urea, creatinine, alanine aminotransferase [ALT], and aspartate aminotransferase [AST]) were observed for any formulation. Emulsivant 70 induced lower reactogenicity at the injection site than Montanide ISA 70. Both adjuvants enhanced IgG and IgG1 responses, but Emulsivant 70 promoted a faster increase in total IgG for both antigens. IFN‐γ levels increased similarly across adjuvanted groups. Following the influenza A challenge, all PR8‐immunized were fully protected. Overall, this study provides the first evidence that Emulsivant 70 is a safe adjuvant that elicits less local reactivity and achieves immunogenicity comparable to Montanide ISA 70, while inducing a faster humoral response. These findings support Emulsivant 70 as a promising alternative for the development of veterinary vaccines.